Merck & Co., Inc. (MRK)

83.00
0.07 0.08
NYSE
Prev Close 82.93
Open 83.20
Day Low/High 82.87 / 83.70
52 Wk Low/High 65.25 / 92.64
Volume 954.30K
Exchange NYSE
Shares Outstanding 2529.24B
Market Cap 210.31B
P/E Ratio 20.13
Div & Yield N.A. (N.A)

Latest News

Parsing the Breakdown of FAANG

Parsing the Breakdown of FAANG

The recent market leaders appear to be running out of steam, while stalwart stocks are grinding higher, with Verizon notable among them.

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.

Jim Cramer: Is This Market Undervalued?

Jim Cramer: Is This Market Undervalued?

Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.

How About That Merck and Seattle Genetics Deal?

How About That Merck and Seattle Genetics Deal?

I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.

Spate of Deal News Juices Start of This Week's Trading

Spate of Deal News Juices Start of This Week's Trading

We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.

This Biotech Appears to Have the Right Formula for Investors

This Biotech Appears to Have the Right Formula for Investors

After reviewing the rally, let's zero in on one biotech name, Genprex, and where it appears to be going.

The Unusual Suspects: Merck, Coca-Cola and 3M

The Unusual Suspects: Merck, Coca-Cola and 3M

Here are three names among the Dow 30 that are setting up nicely.

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'

Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.

Jim Cramer: Betting Against Science Is a Mug's Game

Jim Cramer: Betting Against Science Is a Mug's Game

The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.

Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon

Parabolic AMD, Agreeing to Agree, Disney's GAAP Earnings Gap: Market Recon

It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.

Jim Cramer: Clorox, Covid and Indecision on Packaged Goods Stocks

Jim Cramer: Clorox, Covid and Indecision on Packaged Goods Stocks

The whole group has run and the guidance from Clorox does show, more than anything, that nobody knows.

Grotesque GDP, So Much for Rotation, Amazon Goes Wild: Market Recon

Grotesque GDP, So Much for Rotation, Amazon Goes Wild: Market Recon

Plus, it could be quite a while before the labor market can absorb all those people who are out of jobs.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Novavax and Its $1.6 Billion Award Just Got My Attention

Novavax and Its $1.6 Billion Award Just Got My Attention

The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.

I Wouldn't Buy Pfizer Shares on This Pop

I Wouldn't Buy Pfizer Shares on This Pop

I would wait until the next down day, and there will be one.

Use DRIPs to Build a Socially Responsible Portfolio

Use DRIPs to Build a Socially Responsible Portfolio

Many quality companies that fit into the socially responsible investing camp offer direct-purchase plans, allowing investors an easy way to build an SRI portfolio.

Check Out These 2 Undervalued Drugmakers

Check Out These 2 Undervalued Drugmakers

I plan to add some additional exposure to each on the next 'hiccup' in the market using my usual covered call strategy.

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?

Here's My Take on Seattle Genetics

Here's My Take on Seattle Genetics

The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.

Jim Cramer: Is the Day Where the Virus Ruled Our Lives Waning?

Jim Cramer: Is the Day Where the Virus Ruled Our Lives Waning?

That's the really good news about why we could bounce back so quickly from Thursday's debacle.

Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts

Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts

The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.

Jim Cramer: This Is a Brave New Economy We're In

Jim Cramer: This Is a Brave New Economy We're In

The Fed and Treasury are set on avoiding the mistakes that doomed us in the past, and we have to invest for this new market we're in now.

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.

China Headline Risk, Valuation Station and a Workday Play

China Headline Risk, Valuation Station and a Workday Play

WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.

Equity-a-Palooza, Bank Stocks, Nasdaq 100 in the Red, Trading Thoughts

Equity-a-Palooza, Bank Stocks, Nasdaq 100 in the Red, Trading Thoughts

Rising U.S.-China tensions continue to weigh, but new home sales and stalled continuing jobless claims may be positive catalysts.

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

Perception Continues to Drive the Market

Perception Continues to Drive the Market

The negatives are being shaken off like a first time rider on a long-time bull which means long remains the name of the game.